相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Role of RANK-L as a potential inducer of ILC2-mediated type 2 inflammation in chronic rhinosinusitis with nasal polyps
Noriko Ogasawara et al.
MUCOSAL IMMUNOLOGY (2020)
European Position Paper on Rhinosinusitis and Nasal Polyps 2020
W.J. Fokkens et al.
RHINOLOGY (2020)
A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma
Jenny Lam et al.
JOURNAL OF ASTHMA (2019)
Cost-effectiveness and comparative effectiveness of biologic therapy for asthma To biologic or not to biologic?
William C. Anderson et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2019)
Rationing of Health Care in the United States An Inevitable Consequence of Increasing Health Care Costs
Howard Bauchner
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort
Sarah Faiz et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps
Christopher D. Codispoti et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2019)
A new treatment for chronic rhinosinusitis with nasal polyps
Whitney W. Stevens
LANCET (2019)
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
Claus Bachert et al.
LANCET (2019)
Biologics for the treatment of chronic rhinosinusitis with nasal polyps - state of the art
Lei Ren et al.
WORLD ALLERGY ORGANIZATION JOURNAL (2019)
Proposals to Redesign Medicare Part D - Easing the Burden of Rising Drug Prices
Stacie B. Dusetzina et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
Takanori Numata et al.
BMC PULMONARY MEDICINE (2019)
Biologic Agents for the Treatment of Chronic Rhinosinusitis With Nasal Polyps
Alison G. Kartush et al.
AMERICAN JOURNAL OF RHINOLOGY & ALLERGY (2019)
Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future Directions
Kristine A. Smith et al.
AMERICAN JOURNAL OF RHINOLOGY & ALLERGY (2018)
Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis
Zuzhen Ou et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
M. Castro et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations
R. Brett McQueen et al.
PHARMACOECONOMICS (2018)
Improving the Affordability of Prescription Medications for People with Chronic Respiratory Disease An Official American Thoracic Society Policy Statement
Minal R. Patel et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010-2016
Scott D. Grosse et al.
PEDIATRIC PULMONOLOGY (2018)
Two decades with omalizumab: what we still have to learn
Cristoforo Incorvaia et al.
BIOLOGICS-TARGETS & THERAPY (2018)
Cost Utility Analysis of Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis
George A. Scangas et al.
LARYNGOSCOPE (2017)
Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma
Carlos Iribarren et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial
Claus Bachert et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry
David Fiorentino et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Biotherapeutics in Chronic Rhinosinusitis with and without Nasal Polyps
Claus Bachert et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2017)
Economics of Chronic Rhinosinusitis
Luke Rudmik
CURRENT ALLERGY AND ASTHMA REPORTS (2017)
Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis
Melanie D. Whittington et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2017)
Economic Evaluation of Endoscopic Sinus Surgery Versus Continued Medical Therapy for Refractory Chronic Rhinosinusitis
Luke Rudmik et al.
LARYNGOSCOPE (2015)
Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab
Aidan Long et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma
Philippe Gevaert et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis
Philippe Gevaert et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2011)
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold
Scott D Grosse
Expert Review of Pharmacoeconomics & Outcomes Research (2008)
分享论文
